TrialCardiovascular diabetology2021

Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study.

Matthias Rau et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.